scPharmaceuticals (scPharmaceuticals) Interest Expense : $-8.26 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. scPharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -2.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.26 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. scPharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -15.86 Mil. scPharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -2.10 Mil. scPharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

scPharmaceuticals Interest Expense Historical Data

The historical data trend for scPharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Interest Expense Chart

scPharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.77

-2.59

-2.58

-3.30

-8.12

scPharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.96	-2.01	-2.06	-2.09	-2.10

scPharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.26 Mil.

scPharmaceuticals (NAS:SCPH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

scPharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-2.10 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-15.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $40.62 Mil.

scPharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

scPharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

scPharmaceuticals (scPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

2SX:Germany

Address

2400 District Avenue, Suite 310, Burlington, MA, USA, 01803

Website

https://www.scpharmaceuticals.com

scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Executives

Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar	director	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker	director, officer: President and CEO	INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham	director	C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	other: See Remarks	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	other: See Remarks	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes	officer: See Remarks	C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803